日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study

在FGFR3改变的晚期尿路上皮癌中,厄达替尼在恩福妥单抗治疗之前或之后的疗效:UNITE合作研究分析

Jiang, Cindy Y; Hwang, Hyunsoo; Epstein, Ilana Y; Bakaloudi, Dimitra Rafailia; Talukder, Rafee; Taylor, Amy K; Nizam, Amanda; Jindal, Tanya; Glover, Michael J; Khaki, Ali Raza; Barata, Pedro C; Nguyen, Charles B; Oh, Eugene; Davis, Nancy B; Mabey, Hannah; Hoimes, Christopher J; Evans, Sean T; Abuqayas, Bashar; Lemke, Emily; Tsung, Irene; Qiao, Wei; Kilari, Deepak; Zakharia, Yousef; Bilen, Mehmet A; Milowsky, Matthew I; Shah, Sumit A; Gupta, Shilpa; Emamekhoo, Hamid; Bellmunt, Joaquim; Alva, Ajjai S; Grivas, Petros; Msaouel, Pavlos; Koshkin, Vadim S; Campbell, Matthew T; Alhalabi, Omar

Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma

一项针对晚期透明细胞肾细胞癌的 1b/2 期研究,评估巴替拉西普单药治疗以及联合卡博替尼(加或不加纳武利尤单抗)治疗晚期透明细胞肾细胞癌的疗效。

Beckermann, Kathryn E; Shah, Neil J; Campbell, Matthew T; Haas, Naomi B; Nelson, Ariel; Ornstein, Moshe C; Mao, Shifeng; Keshava-Prasad, Holavanahalli S; Hammers, Hans; Gao, Xin; Gourdin, Theodore; George, Saby; Hoimes, Christopher J; Hussain, Arif; Jonasch, Eric; Rini, Brian I; Voss, Martin H

Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study

接受恩福妥单抗治疗的晚期尿路上皮癌患者的治疗相关不良事件及相关结局:UNITE 研究分析

Nizam, Amanda; Nguyen, Charles B; Li, Jinju; Zabor, Emily C; Msaouel, Pavlos; Jiang, Cindy Y; Alhalabi, Omar; Oh, Eugene; Davidsohn, Matthew P; Epstein, Ilana B; Bakaloudi, Dimitra Rafailia; Talukder, Rafee; Jindal, Tanya; Taylor, Amy K; Glover, Michael J; Khaki, Ali Raza; Lemke, Emily; Mabey, Hannah; Abuqayas, Bashar; Jang, Albert; Brown, Jason R; Evans, Sean T; Pywell, Cameron; Basu, Arnab; Bilen, Mehmet A; Barata, Pedro C; Zakharia, Yousef; Milowsky, Matthew I; Kilari, Deepak; Hoimes, Christopher J; Shah, Sumit A; Emamekhoo, Hamid; Davis, Nancy B; Gupta, Shilpa; Grivas, Petros; Bellmunt, Joaquim; Campbell, Matthew T; Alva, Ajjai S; Koshkin, Vadim S

Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting

住院患者接受恩福妥单抗和帕博利珠单抗治疗期间,识别和管理不良皮肤反应

Myers, Emma L; Liu, Jessica; Shearer, Sabrina M; Myers, Sarah A; Schneider, Michelle; Hoimes, Christopher; Whitley, Melodi Javid

Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab

晚期尿路上皮癌患者(不适合接受顺铂治疗)接受一线恩福妥单抗单药治疗或联合帕博利珠单抗治疗的患者报告结局

Milowsky, Matthew I; O'Donnell, Peter H; Hoimes, Christopher J; Petrylak, Daniel P; Flaig, Thomas W; Moon, Helen H; Friedlander, Terence W; Mar, Nataliya; McKay, Rana R; Srinivas, Sandy; Gravis, Gwenaelle; Ramamurthy, Chethan; Bupathi, Manojkumar; Bracarda, Sergio; Wright, Phoebe; Hepp, Zsolt; Carret, Anne-Sophie; Yu, Yao; Dillon, Ryan; Kataria, Ritesh; Beaumont, Jennifer L; Purnajo, Intan; Rosenberg, Jonathan E

Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)

改良的白细胞介素-2 细胞因子 Nemvaleukin alfa 作为单药疗法以及与 pembrolizumab 联合治疗晚期实体瘤患者(ARTISTRY-1)

Vaishampayan, Ulka N; Muzaffar, Jameel; Winer, Ira; Rosen, Seth D; Hoimes, Christoper J; Chauhan, Aman; Spreafico, Anna; Lewis, Karl D; Bruno, Debora S; Dumas, Olivier; McDermott, David F; Strauss, James F; Chu, Quincy S; Gilbert, Lucy; Chaudhry, Arvind; Calvo, Emiliano; Dalal, Rita; Boni, Valentina; Ernstoff, Marc S; Velcheti, Vamsidhar

High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

高剂量静脉注射维生素C联合多西他赛治疗转移性去势抵抗性前列腺癌男性患者:一项随机安慰剂对照II期试验

Paller, Channing J; Zahurak, Marianna L; Mandl, Adel; Metri, Nicole A; Lalji, Aliya; Heath, Elisabeth; Kelly, William K; Hoimes, Christopher; Barata, Pedro; Taksey, Jason; Garrison, Dominique A; Patra, Kartick; Milne, Ginger L; Anders, Nicole M; Nauroth, Julie M; Durham, Jennifer N; Marshall, Catherine H; Markowski, Mark C; Eisenberger, Mario A; Antonarakis, Emmanuel S; Carducci, Michael A; Denmeade, Samuel R; Levine, Mark

A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab

一份通俗易懂的摘要,探讨一种用于治疗未经治疗的局部晚期或转移性尿路上皮癌的新疗法组合:恩福妥单抗联合帕博利珠单抗

Hoimes, Christopher J; Flaig, Thomas W; Milowsky, Matthew I; Friedlander, Terence W; Bilen, Mehmet Asim; Gupta, Shilpa; Srinivas, Sandy; Merchan, Jaime R; McKay, Rana R; Petrylak, Daniel P; Sasse, Carolyn; Moreno, Blanca Homet; Yu, Yao; Carret, Anne-Sophie; Rosenberg, Jonathan E

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

恩福妥单抗联合或不联合帕博利珠单抗治疗既往未接受治疗的局部晚期或转移性尿路上皮癌患者(不适合顺铂治疗)

O'Donnell, Peter H; Milowsky, Matthew I; Petrylak, Daniel P; Hoimes, Christopher J; Flaig, Thomas W; Mar, Nataliya; Moon, Helen H; Friedlander, Terence W; McKay, Rana R; Bilen, Mehmet A; Srinivas, Sandy; Burgess, Earle F; Ramamurthy, Chethan; George, Saby; Geynisman, Daniel M; Bracarda, Sergio; Borchiellini, Delphine; Geoffrois, Lionnel; Maroto Rey, Jose Pablo; Ferrario, Christiano; Carret, Anne-Sophie; Yu, Yao; Guseva, Maria; Homet Moreno, Blanca; Rosenberg, Jonathan E

Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

Enfortumab Vedotin 联合 Pembrolizumab 治疗既往未接受治疗的晚期尿路上皮癌

Hoimes, Christopher J; Flaig, Thomas W; Milowsky, Matthew I; Friedlander, Terence W; Bilen, Mehmet Asim; Gupta, Shilpa; Srinivas, Sandy; Merchan, Jaime R; McKay, Rana R; Petrylak, Daniel P; Sasse, Carolyn; Moreno, Blanca Homet; Yu, Yao; Carret, Anne-Sophie; Rosenberg, Jonathan E